(PA-378) Steady-state Hematopoietic Cell Mobilization for Newly Diagnosed Multiple Myeloma Patients Receiving Daratumumab-based Induction Therapy versus Imid-based Induction Therapy: A Real- world Experience

Daratumumab-based induction therapy have recently become the standard of

care for patients with newly diagnosed multiple myeloma who are candidates for autologous stem cell transplantation. Previous reports have shown that daratumumab might impair stem cell mobilization and collection, leading to an
increased requirement for plerixafor use and impaired stem cell engraftment. In the context of Daratumumab, protocols for mobilization vary significantly. Therefore, we conducted a single-center retrospective analysis in order to evaluate steady-state stem cell mobilization and harvest in patients receiving daratumumab-based induction therapy versus IMiD-based induction therapy.

Methods:   From Jan 2023 till May 2025, we retrospectively reviewed patients receiving daratumumab-based induction therapy and IMiD-based induction therapy followed by stem cell mobilization in a steady-state protocol using 10 μg/kg granulocyte colony-stimulating factor (G-CSF) for 5 days.

Results:   Overall,110 patients (daratumumab-based 16 patients, IMiD-based 94 patients) were included in the analysis. Patient characteristics were well balanced between groups. There was no significant difference in median days of apheresis to reach the patient-specific CD34+ goal and mean cumulative CD34+ cell collection. Plerixafor was used in 68.7% (daratumumab-based) and 39.3% (IMiD-based) cases (p = 0.008).

Conclusions:   

Steady-state hematopoietic cell mobilization in patients undergoing daratumumab-based induction therapy is feasible, although patients with daratumumab-based induction therapy more frequently requires plerixafor.